公开(公告)号：US12201592B2

公开(公告)日：2025-01-21

申请号：US17159798

申请日：2021-01-27

Applicant: TYRNOVO LTD.

Inventor： Hadas Reuveni ,  Izhak Haviv ,  Lana Kupershmidt

IPC: A61K31/165 ,  A61K31/436 ,  A61K31/4375 ,  A61K31/505 ,  A61K31/517 ,  A61K31/519 ,  A61K39/395 ,  C07K16/28

Abstract: Provided is a treatment of cancer using a dual modulator of Insulin Receptor Substrate (IRS) and signal transducer and activator of transcription 3 (Stat3), as well with other agents. The combination can be used to treat a tumor that has developed resistance to an EGFR inhibitor, EGFR antibody, mTOR inhibitor, MEK inhibitor, mutated B-Raf inhibitor, chemotherapeutic agents, and certain combinations thereof, or to prevent acquired resistance of a tumor to any of said inhibitors or agents, or to prevent tumor recurrence following cease of treatment with any of said inhibitors or agents or a combination thereof. The subject matter further provides a treatment of cancer using combination therapy comprising a dual modulator of IRS and Stat3, in combination with an immunotherapy agent. The combination can be used to sensitize a tumor to immunotherapy.

公开(公告)号：US10912745B2

公开(公告)日：2021-02-09

申请号：US15548915

申请日：2016-02-04

Applicant: TYRNOVO LTD.

Inventor： Hadas Reuveni ,  Izhak Haviv ,  Lana Kupershmidt

IPC: A61K31/165 ,  A61K31/436 ,  A61K31/517 ,  A61K31/519 ,  A61K31/505 ,  A61K31/4375 ,  A61K39/395 ,  C07K16/28

Abstract: Provided is a treatment of cancer using a dual modulator of Insulin Receptor Substrate (IRS) and signal transducer and activator of transcription 3 (Stat3), as well with other agents. The combination can be used to treat a tumor that has developed resistance to an EGFR inhibitor, EGFR antibody, mTOR inhibitor, MEK inhibitor, mutated B-Raf inhibitor, chemotherapeutic agents, and certain combinations thereof, or to prevent acquired resistance of a tumor to any of said inhibitors or agents, or to prevent tumor recurrence following cease of treatment with any of said inhibitors or agents or a combination thereof. The subject matter further provides a treatment of cancer using combination therapy comprising a dual modulator of IRS and Stat3, in combination with an immunotherapy agent. The combination can be used to sensitize a tumor to immunotherapy.